COVID-19 Updates

Johnson & Johnson/Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS): Update for Clinicians

You may participate in this COCA Call via Zoom


This COCA Call will present the latest evidence on thrombosis with thrombocytopenia syndrome (TTS) after administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers will discuss information on TTS and updated vaccine recommendations.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

The slide set will be available under “Call Materials” on the COCA Call webpage the day of the call.

Continuing Education (CE) will not be provided for this call.

Advanced registration is not required.

Date: Tuesday, April 27, 2021

Time: 2:00 pm – 3:00 pm (ET)

A few minutes before the webinar starts, please click on the Zoom link below to join:



Or one-tap mobile: 

US: +16692545252,,1601111927#,,,,*358595#



Or Telephone: Dial (for higher quality, dial a number based on your current location): 

US: +1 669 254 5252 or

+1 646 828 7666 or

+1 551 285 1373 or

+1 669 216 1590

Webinar ID: 160 111 1927


International numbers available:

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following—
  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.


Sara Oliver, MD

LCDR, U.S. Public Health Service

Co-lead, Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group

COVID-19 Response

Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA

CAPT, U.S. Public Health Service

Vaccine Safety Team Lead

COVID-19 Response

Centers for Disease Control and Prevention

The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at

CDC - Centers for Disease Control and PreventionCDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.